Skip to content

Study on the anti photaesthesia mixture in the treatment of light invasive polymorphous light eruption of clinical efficacy and safety evaluation and improvement

Study on the anti photaesthesia mixture in the treatment of light invasive polymorphous light eruption of clinical efficacy and safety evaluation and improvement

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003894
Enrollment
Unknown
Registered
2013-08-23
Start date
2012-07-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polymorphous light eruption

Interventions

Treatment group:anti photaesthesia mixture
Control:without anti photaesthesia mixture

Sponsors

Beijing Chinese Medicine Hospital affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. accord with the standard of polymorphous light eruption diagnosis of Western medicine; 2. in line with the traditional Chinese medicine phototoxic invasion card "syndrome diagnosis criterion sun sores" card; 3. between the ages of 18 to 65 years old; 4. the severity of the rash area: <5cm-square.

Exclusion criteria

Exclusion criteria: 1. the exposed parts of the other inflammatory skin diseases, such as hair coloring dermatitis, contact dermatitis; 2. the disease such as systemic increased light sensitivity, dermatomyositis, systemic lupus erythematosus; 3. cardiovascular, hepatic,renal, endocrine, hematopoietic system and other serious diseases, or suffering from mental illness, affect the finish; 4. pregnant or lactating women; 5. known or suspected of drug allergy; 6. with dyspnea, chest tightness, shortness of breath, palpitation, nausea, vomiting, dizziness and other system symptoms; 7. are participating in other clinical trials of patients; 8. researchers think should not participate in the test.

Design outcomes

Primary

MeasureTime frame
minimal erythema dose (MED);blood routine test;

Secondary

MeasureTime frame
blood routine;blood biochemistry tests;lesion severity score;

Countries

China

Contacts

Public ContactLiyun Sun

Beijing Chinese Medicine Hospital affiliated to Capital Medical University

doctorsunny@sina.cn+86 13521779789

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026